Search

Displaying results 2301 - 2310 of 10000 in total
  1. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. … Vayarin is currently available only by prescription in the USA [L1502]. This drug has also been used for management of hypertriglyceridemia [L1503].

  2. Drug

    Indium In-111 pentetate

    go.drugbank.com/drugs/DB09425
    ApprovedInvestigational

    Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. … Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

    Synonyms: Indium In 111 pentetate, Indium In-111 pentetateSalts: Indium In-111 pentetate disodium
  3. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.

  4. Drug

    Iobitridol

    go.drugbank.com/drugs/DB12407
    ApprovedWithdrawn

    Iobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. … Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.

    Synonyms: N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriol
  6. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype

  7. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    FDA approved on June 15, 2011. … It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.

  8. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.

    Categories: Sympathomimetics in Glaucoma Therapy
  9. Drug

    Testosterone cypionate

    go.drugbank.com/drugs/DB13943
    ApprovedInvestigational

    Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. … It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.

  10. Drug

    Loxapine

    go.drugbank.com/drugs/DB00408
    ApprovedInvestigational

    An antipsychotic agent used in schizophrenia. [PubChem]